Roble Belko & Company’s iShares Biotechnology ETF IBB Stock Holding History

Roble Belko & Company’s Portfolio IBB Stock Details IBB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-212	Closed	-$29K	–	331
2020 Q2	$29K	Hold	212	–	–	0.01%	170
2020 Q1	$23K	Hold	212	–	–	0.01%	184
2019 Q4	$26K	Hold	212	–	–	0.01%	190
2019 Q3	$21K	Hold	212	–	–	0.01%	194
2019 Q2	$23K	Buy	+212	New	+$22.6K	0.01%	190

Other funds holding IBB

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Churchill Management Los Angeles, California $9.21B AUM 19.91% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Roble Belko & Company's IBB Position: Q3 2020 in Review

Roble Belko & Company sold out of iShares Biotechnology ETF (IBB) in Q3 2020, closing a stake of 212 shares — an estimated $29K sold.

Roble Belko & Company first reported a position in IBB in Q2 2019 and held it in 5 quarters. The position peaked at $29K in Q2 2020. 784 funds tracked by Wall St. Rank hold IBB as of Q3 2020.

Roble Belko & Company reported no remaining iShares Biotechnology ETF position as of Q3 2020 after selling out during the quarter.
Roble Belko & Company sold 212 iShares Biotechnology ETF shares in Q3 2020, an estimated $29K.
Roble Belko & Company first reported a position in iShares Biotechnology ETF in Q2 2019 and held it in 5 quarters.
Roble Belko & Company's iShares Biotechnology ETF position peaked at $29K in Q2 2020.
784 funds tracked by Wall St. Rank held iShares Biotechnology ETF as of Q3 2020.

Based on Roble Belko & Company's 13F filing for Q3 2020, filed 10 Nov 2020.